%0 Clinical Trial
%T [Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection].
%A Escobedo-Sánchez PE
%A de la Cruz-Hernández I
%A Ramos-García M
%A Sánchez-Yedra I
%A García-Vázquez C
%A Guzmán-Priego CG
%A García-Vidrios MV
%A Olvera-Hernández V
%A Mendoza-García Y
%A Ble-Castillo JL
%J Med Clin (Barc)
%V 161
%N 8
%D 2023 10 27
%M 37423879
%F 3.2
%R 10.1016/j.medcli.2023.05.013
%X During the COVID-19 pandemic, several strategies were suggested for the management of the disease, including pharmacological and non-pharmacological treatments such as convalescent plasma (CP). The use of CP was suggested due to the beneficial results shown in treating other viral diseases.<BR>To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.<BR>Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.<BR>The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.<BR>Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.